Plain-English translation of NCT07109726 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is an early-stage clinical trial testing a new drug called in patients with advanced solid tumors that have specific genetic mutations. Researchers want to understand how safe this medication is, how your body processes it, and whether it can help fight your cancer. The trial will test alone and also in combination with another medication called fulvestrant, which is already used to treat certain breast cancers.
Many cancers have mutations in genes that control cell growth (the AKT/PI3K/PTEN pathway). Currently, there are limited treatment options for patients whose tumors have these specific mutations. This medication is designed to target and block these faulty genes, potentially offering a new way to treat several types of advanced cancer.
You likely qualify if…
You likely don't qualify if…
The trial has two phases. First, researchers will gradually increase doses of the medication in small groups to find the safest dose (dose escalation). Then, larger groups of patients will receive that safe dose to see how well it works (dose expansion). You will take the medication by mouth, likely daily, and visit the clinic regularly for blood tests, scans, and check-ups to monitor your health and how your cancer responds. The study may last several months or longer depending on how you respond to treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States